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Cell proliferation of the uninvolved psoriatic skin was 
compared with normal skin of volunteers following stim-
ulation by the intradermal injections of saline or pro-
pranolol, or stripping of the stratum corneum with pres-
sure-sensitive tape. Initially, no significant in vivo differ-
ence in tritiated thymidine labeling indices were ob-
served between normal and uninvolved epidermal cells. 
However, 48 hr after each stimulus more DNA synthe-
sizing cells were found in the uninvolved psoriatic than 
in normal epidermis. Of these 3 stimuli, propranolol was 
the most effective in distinguishing between uninvolved 
psoriatic skin and skin from normal control subjects. 
Thus, uninvolved psoriatic skin appears to possess an 
abnormal regulation of epidermopoiesis that may be 
a:rnplified by propranolol injection. 
The experimental production of psoriatic lesions in clinically 
uninvolved "normal" skin of psoriatic patients (Koebner phe-
nomenon) has led to many studies of the uninvolved skin for 
clues into the pathogenesis of psoriasis. While the uninvolved 
skin apparently differs from normal skin in such diverse prop-
erties as tetracycline binding (1) cholesterol esterification (2), 
and vascular reactions (3), any meaningful abnormality must 
ultimately cause increased epidermal proliferation since pso-
riatic skin lesions are hyperplastic islands of tissue with in-
creased epidermopoiesis [4-7]. One in vivo study suggests that 
nonspecifically stimulated uninvolved psoriatic skin is prone to 
abnormally increased epidermopoiesis [8]. Moreover, observa-
tions that flares of psoriasis sometimes follow systemic admin-
istration of certain drugs (such as chioroquin, cortisone, and 
lithium) and bacterial infections (e.g., streptococcal) suggest 
the possibility of specific pharmacologic and bacteriologic "trig-
gers" of psoriasis. The purpose of this study, therefore, was to 
find a biochemical compound that would selectively "trigger" 
a proliferative response in uninvolved psoriatic skin not ob-
served in normal skin. 
Recent evidence that the psoriatic skin has defective stimu-
la tion of cyclic AMP by ,B-adrenergic agonists [9-11] and reports 
of a psoriasiform derma titis occasionally caused by treatment 
with ,B-adrenergic blocking agents (such as practolol and pro-
pranolol) [12,13] led us to select propranolol as a pharmacologic 
probe for inducing a specific abnormality of epidermal prolif-
eration in uninvolved psoriatic skin. In vivo tritiated thymidine 
and auto radiographic techniques were used to quantitate cell 
proliferation. 
MATERIALS AND METHODS 
Patient Selection 
Informed volunteers were divided into a psoriasis group and a 
"normal" control group. Individuals were excluded if they were under 
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40 yr of age, had some contraindication to the use of propranolol, or 
were taking methotrexate, systemic steroids, indomethacin, or aspirin. 
No patient was studied who had applied an active topical compound to 
the buttock skin within 2 weeks prior to this study. To be included in 
the psoriasis group, volunteers had to have classic plaque-stage psoriasis 
and a beneficial response at some time to an accepted treatment of 
psoriasis. To be included in the normal group, no clinical or historical 
evidence of psoriasis could be present (including papulosquamous le-
sions on the body, detectible seborrheic dermatitis, unexplained nail 
abnormalities, chronic palmar-plantar lesions, arthritis, or family his-
tory of psoriasis). 
Protocol 
Normal-appearing buttock skin was studied in all cases. All patients 
were tested about the same time of day (i.e., afternoon). On the fIrst 
day of the study, test sites were cleansed with 70% alcohol swabs and 
then injected intradermally using 30 gauge needles with 0.1 cc of the 
appropriate study compound or treated by repetitively stripping the 
skin with pressure-sensitive tape (Scotch brand cellophane tape) until 
glistening indicated removal of stratum corneum. Baseline values were 
obtained by intradermal injections of the appropriate test areas ap-
proximately 10 min later with 0.1 cc. of trit iated thymidine (New 
England Nuclear, 5 J-L CiJ-L/ O.l cc, sp. act. 6.7 ci/ mJ-L). Skin biopsies were 
then performed 30 min later (40 min after the test compound injection) 
with a 4-mm punch using 1% xylocaine without epinephrine for local 
anesthesia. Other time values were obtained by waiting 24, 48, or 72 hr 
after the test compound or tape stripping before injecting tritiated 
thymidine and then biopsying 30 min later. All specimens were proc-
essed for autoradiography as previously described [5] and exposed for 
2 weeks. The number of labeled interfollicular epidermal cells per 
sections (LC) were counted on coded slides. A total of 2 sections for 
each test site were counted. The surface length of each section was 
measured with an ocular micrometer. During the study no topical 
agents were applied to the study area. 
Preliminary studies with 0.1 mg, 0.01 mg, and 0.001 mg propranolol 
injections indicated that 0.1 mg was the most effective concentration 
for separating uninvolved psoriatic skin from normal skin. The remain-
ing experiments, therefore, utilized 0.1 cc (0.1 mg) of injectable d,l 
propranolol hydrochloride (injectable Inderal, Ayerst, consisting of d,l 
propranolol hydrochloride, water, and citric acid added to obtain a pH 
of 3.0) for the determination of baseline (0 hr), 24 hr, 48 hr, and 72 hr 
values. The purpose of the fIrst part of the study was to determine the 
time course Gf increased labeling after propranolol injection. In the 
same patients, injection of normal saline and pressure-sensitive tape 
stripping were also performed. 
The results of the fIrst part of the study showed that peak cell 
proliferation occurred between 24 and 72 hr after propranolol injection. 
In the second part of the study 0 and 48 hr values were determined 
after propranolol injection and normal saline injection in all volunteers. 
Forty-eight hour values following pressure-sensitive tape stripping were 
determined in all subjects. 
In the third part of the study, 48 hr values were determined following 
propranolol injection, normal saline injection, and a pH-adjusted, to-
nicity-adjusted control (for the vehicle of the propranolol solution) 
solu tion (4.7 mg citric acid, 4.6 mg NaCI in 20 cc distilled water) 
injection in all volunteers. 
RESULTS 
Figure 1 shows that the peak increase in the number of 
labeled cells and mitoses occurs between 24 and 72 hr after 
injection of 0.1 mg. of propranolol. Forty-eight hours after 
injecting propranolol in normal-appearing skin of 13 psoriatic 
patients, a mean of 163 ± 49 (standard deviation) LC was 
present compared to 70 ± 33 in the nonpsoriatic volunteers (p 
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> .001 using Student t-test). Mean surface length of sections 
was 3.5 nun ± 0.1 in both groups. A mean baseline value after 
propranolol of 32 ± 14 LC (9 patients) in the psoriasis group, 
although higher, was not statistically different from the baseline 
value of 27 ± 23 (5 patients) in the nonpsoriatic group (Student 
t-test ). The baseline values after saline injections were 43 ± 22 
(13 patients) and 22 ± 12 (9 patients) in uninvolved and normal 
skin respectively, and were not significantly different from each 
other or from the propranolol baseline values. Peak L.C. values 
for saline injections (107 ± 59 uninvolved psoriatic skin, 52 ± 
31 control skin) were observed at 48 hr. The scattergram in Fig 
2 depicts significant differences between the 2 types of skin 48 
hr after saline injection, propranolol injection, and pressure-
sensitive tape stripping. Following all 3 stimuli the uninvolved 
psoriatic skin reacted with higher labeling than normal skin 
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FIG 1. Cell proliferation a t different times after propranolol injection 
into the uninvolved psoria t ic skin compared to normal skin. 
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FIG 2. Number of labeled cells/section 48 hr after saline injection, 
propranolol injection, and tape stripping of uninvolved psoriatic skin 
(UPS) compared to normal skin (NS). 
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although propranolol produced the most discrete separation 
between the groups. 
In 9 additional subjects with psoriasis the mean LC 48 hr 
after injecting propranolol 0.1 mg (150 ± 52 L.C.) was signifi-
cantly different from the mean 48 hr after injecting the vehicle 
solution which was matched with the propranolol solution for 
pH and tonicity (118 ± 55 LC, p < .001 using a paired-compar-
ison Student t-test) . Using the same statistical test, the pH-
adjusted and tonicity-adjusted vehicle solution was not signifi-
cantly different from normal saline (115 ± 50 LC). Thus, the 
pH and tonicity of the propranolol solution does not affect 
labeling in uninvolved psoriatic skin. 
Figure 3 shows the component of the increase in LC 48 hr 
after propranolol injection that occurs above that produced by 
saline injection alone. The mean saline value of 107 ± 59 LC in 
the psoriasis group is significantly different from the mean of 
163 ± 49 observed after propranolol injection (p > .01 using 
paired Student t-test). At 48 hr in the normal controls, however, 
the mean of the propranolol injected sites is slightly higher but 
not significantly different than the saline injected sites (70 ± 33 
L.C. vs 52 ± 31). Thus, even though both saline and propranolol 
produce more labeling in uninvolved psoriatic skin than normal 
control skin 48 hr after injection, propranolol evokes a greater 
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FIG 3. Component of increased labeling attributed to "propranolol 
effect" in uninvolved psoriatic skin (UPS) and normal skin (NS) . 
B 
" ~ 
" *,. • 
, ~ ~~ . 
-. .. ....... ~ .... . , '.11' , .. \ \ 
FIG 4. Comparison of labeling immediately after propranolol injec-
tion in uninvolved psoriatic skin (A) and 48 hr after propranolol 
injection (B). Labeled cells are confined to the lower 2-3 epidermal cell 
layers. (reduced from X 134). 
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increase apparently specific for uninvolved psoriatic skin. Pro-
pranolol appears to have no significant effect on normal control 
skin compared to saline. 
Figure 4 shows a photomicrograph of labeling 48 hr after the 
propranolol injection into uninvolved psoriatic skin compared 
to baseline labeling. In all sections examined, the labeled cells 
were found in the lower 2-3 cell layers of epidermis showing 
that increased labeling occurred not only in the basal cell layers 
but apparently by recruitment of cells from the second and 
possibly third cell layers. 
DISCUSSION 
Compared to normal skin, uninvolved psoriatic skin has a 
greater proliferative response 48 hr after propranolol injection, 
saline injection and tape stripping. Of these stimuli saline is the 
weakest inducer of proliferation as measured by tritiated thy-
midine labeled cells while tape stripping is the strongest. This 
finding of a greater number of labeled cells/section in unin-
volved psoriatic skin than in normal skin after nonspecific 
stimulation confums a similar observation made by Braun-
Falco, Christophers, and Kurban [8] who studied the labeling 
with tritiated thymidine after pressure-sensitive tape stripping 
in normals and psoriatics. The in vitro observation that in-
creased labeling occurs in tissue explants of uninvolved psoriatic 
skin compared to normal skin [14] may be analogous to the 
current in vivo studies. Both observations may reflect an ab-
normal predisposition for uninvolved psoriatic skin to prolifer-
ate more rapidly after a variety of stimuli. Clinically, this 
tendency probably finds expression as the Koebner phenome-
non. In this study, chemical induction of psoriatic lesions with 
propranolol was not seen since all injected sites were biopsied 
by 48-72 hr. 
Despite the fact that tape stripping was the strongest stimu-
lus for proliferation, propranolol was most effective in differ-
entiating uninvolved psoriatic skin from normal skin in terms 
of least overlap between groups. That the strongest stimulus 
for proliferation was not the best discriminating stimulus be-
tween the groups raises the possibility that propranolol may be 
acting more specifically than the other stimuli tested. This 
possible selectivity suggests that propranolol may be biochem-
ically altering a defective modulator of epidermopoiesis in un-
involved psoriatic skin above that seen with saline control 
injections. Experiments with a control solution adjusted for pH 
and tonicity eliminate the possibility of the specific effect being 
caused by these 2 physical properties in the propranolol vehicle 
solution. The mechanism or biochemical site at which propran-
olol causes this disproportionately increased proliferative re-
sponse in psoriasis can only be speculated on at this time. 
The fmding of increased cell proliferation after propranolol 
injection has several counterparts in other experimental sys-
tems. Tutton and Helme [15] found that propranolol shortened 
cell cycle time in the crypts of rat jejunum. Winchurch and 
Mardiney [16] have shown that propranolol enhances antigen-
induced lymphocyte blastogenesis. Both of these effects are 
mediated by the ,B-adrenergic blocking properties of proprano-
lol. 
If one assumes that this abnormality of cell proliferation in 
the uninvolved psoriatic skin is primarily related to the patho-
genesis of psoriasis, this investigation leads to several specula-
tions about epidermal proliferation in psoriasis. First, the time 
from a stimulus until peak of LC is approximately similar in 
normal and uninvolved skin. Therefore, the biochemical steps 
from the time that the cell received a signal to begin DNA 
synthesis until DNA synthesis begins may be similar in both 
tissues. Second, return to baseline LC is similar in both tissues. 
Therefore, the mechanism involved in "turning off' or limiting 
cell proliferation seems to function similarly in both tissues. 
Finally, the additional cells recruited into the DNA synthesis 
phase can come either from a speed up of G) cells, from a 
possible Go cell population (if this indeed exists in epidermis) or 
from the "dedifferentiation" of cells. Thus, in uninvolved pso-
riatic epidermis, either GJ, Go or differentiated cells must have 
a special predisposition to be recruited into S by propranolol as 
well as less specific stimuli. 
Whatever the pathogenesis of the increased cell recruitment 
in uninvolved psoriatic skin after various stimuli, practical 
application as a marker of a latent proliferative abnormality in 
psoriasis may be possible, especially using propranolol as a 
stimulus. Such a marker, if it can be shown to be fundamentally 
related to the cause of psoriasis, would be useful in genetic as 
well as biochemical studies. 
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